Zylberberg B, Salat-Baroux J, Ravina J H, Dormont D, Amiel J P, Diebold P, Izrael V
Cancer. 1982 Apr 15;49(8):1537-43. doi: 10.1002/1097-0142(19820415)49:8<1537::aid-cncr2820490805>3.0.co;2-e.
Fifteen patients with clinical primary inflammatory carcinoma of the breast were treated with initial chemoimmunotherapy between September 1974 and May 1977. The protocol was a combination of Adriamycin, vincristine, 5-fluorouracil, and methotrexate given by I.V. push, and melphalan per os. Thermographic cooling was taken as the criterion of operability. Initial chemotherapy was resumed after surgery up to a total of ten courses and followed by maintenance chemotherapy for a minimum of one year. Immunotherapy using I-BCG-F. Pasteur was routinely associated with the antimitotic agents. The median survival for our 15 patients has not been reached and exceeds 56 months. These results correspond to an obvious therapeutic benefit compared with recent attempts in which similar chemoimmunotherapy protocols were used; this benefit seems to be the consequence of the adaptation of the length of initial chemotherapy to the data given by plate-thermography.
1974年9月至1977年5月期间，对15例临床原发性炎性乳腺癌患者进行了初始化学免疫治疗。治疗方案为静脉推注阿霉素、长春新碱、5-氟尿嘧啶和甲氨蝶呤，以及口服美法仑。以热像图降温作为可手术性的标准。术后继续进行初始化疗，总共10个疗程，随后进行至少一年的维持化疗。使用巴斯德I-BCG-F进行免疫治疗通常与抗有丝分裂药物联合使用。我们这15例患者的中位生存期尚未达到，超过了56个月。与最近使用类似化学免疫治疗方案的尝试相比，这些结果显示出明显的治疗益处；这种益处似乎是初始化疗疗程长度根据热板成像数据进行调整的结果。
